First Clinical Evaluation of Tarumase® for Debridement in Venous Leg Ulcers

First Clinical Evaluation of Tarumase® for Debridement in Venous Leg Ulcers

In this Podiatry Today video demonstration, clinicians present initial real-world data on **Tarumase®**, an enzymatic debriding agent, used for treating venous leg ulcers. The video follows its application in a clinical and outpatient context.

Key Highlights:

  • Tarumase® Application: Applied topically to venous leg ulcer beds and covered with a semi‑permeable dressing, allowing enzymatic breakdown of non‑viable tissue while preserving healthy tissue.
  • Clinical Efficacy: Initial cases demonstrate visible devitalized tissue removal within 24–48 hours, reducing manual debridement needs and enhancing wound bed readiness.
  • Safety & Patient Comfort: Patients reported minimal pain and no systemic side effects. Application was well‑tolerated in outpatient settings, even in patients with comorbidities. :contentReference[oaicite:1]{index=1}
  • Workflow Benefits: Clinicians highlighted that Tarumase® simplifies debridement protocols, enabling more efficient treatment cycles and better integration into multidisciplinary wound care routines.

This video provides a promising look at Tarumase® as an enzyme-based debridement tool that could complement or reduce dependence on sharp or mechanical methods in venous leg ulcer management.

Watch the full video on the HMP Global Learning Network.

Keywords:
Tarumase®,
venous leg ulcer,
enzymatic debridement,
outpatient care,
patient tolerance


🔬 Spotlight: Tarumase® – Enzymatic Precision for Wound Debridement

Tarumase® is an advanced enzymatic debriding agent formulated to selectively break down necrotic tissue in chronic wounds—particularly venous leg ulcers—while preserving healthy granulating tissue. This topical therapy offers a gentle, effective alternative to mechanical or sharp debridement, making it suitable for both inpatient and outpatient wound care settings.

Early clinical evaluations highlight Tarumase’s ability to:

  • Visibly reduce devitalized tissue within 24–48 hours
  • Minimize pain and trauma during dressing changes
  • Streamline wound bed preparation without requiring surgical expertise

Its targeted enzymatic action and user-friendly application have positioned Tarumase® as a valuable tool in modern wound healing protocols, especially for patients with comorbidities or limited surgical access.